

# Quality Management Activity Guiding Questions

Activity Title: The Case of an FDA Letter 1

## Activity Guiding Questions:

1. What is the nature of the citation?

---

---

---

---

2. According to the citation, what were the general responsibilities of the clinical investigator at the site?

---

---

---

---

3. Keeping Good Clinical Practices (GCP) Guidelines in mind could this citation have been prevented from happening? If so, how?

---

---

---

---

4. At your tables, discuss and identify any violations cited in the excerpts identified in the citation.

---

---

---

---



# Quality Management Activity Guiding Questions

Activity Title: The Case of an FDA Letter 2

## Activity Guiding Questions:

1. What is the nature of the citation?

---

---

---

2. According to the citation, what were the general responsibilities of the clinical investigator at the site?

---

---

---

3. Keeping Good Clinical Practices (GCP) Guidelines in mind could this citation have been prevented from happening? If so, how?

---

---

---

4. At your tables, discuss and identify any violations cited in the excerpts assigned to them. (Share ICH reference)

---

---

---

5. As a group explain how this citation affect the safety of the participants.

---

---

---



# Quality Management Activity Guiding Questions

Activity Title: The Case of an FDA Letter 3

## Activity Guiding Questions:

1. What is the nature of the citation?

---

---

---

---

2. According to the citation, what were the general responsibilities of the clinical investigator at the site?

---

---

---

---

3. Keeping Good Clinical Practices (GCP) Guidelines in mind could this citation have been prevented from happening? If so, how?

---

---

---

---

4. At your tables, discuss and identify any violations cited with regards to each participant in the excerpts assigned to your group. (Share ICH reference)

---

---

---

---

5. As a group explain how this citation affect the safety of the participants.

---

---

---

---

6. Was the written response provided by the CI adequate per FDA findings? If not, as a group discuss why is was not and generate a list of the responses provided by CI and the FDA determination.



# Quality Management Activity Guiding Questions

Activity Title: The Case of an FDA Letter 4

## Activity Guiding Questions:

1. What is the nature of the citation?

---

---

---

---

---

2. According to the citation, what were the general responsibilities of the clinical investigator at the site? And what did he/she failed to do? Include samples of these.

---

---

---

---

---

3. Keeping Good Clinical Practices (GCP) Guidelines in mind could this citation have been prevented from happening? If so, how?

---

---

---

---

---

4. At your tables, discuss and identify any violations cited in the excerpts assigned to them. (Share ICH reference)

---

---

---

---

5. As a group explain how this citation affect the safety of the participants.

---

---

---

---

---

